Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of metastatic uveal melanoma

Humanistic burden and health-related quality of life

7 evidence topics · 10 sources

EORTC QLQ-C30 global health status and EQ-5D visual analogue scale in the IMCgp100-202 tebentafusp trial, intent-to-treat analysis set
EORTC QLQ-C30 global health status (score 0 to 100)Tebentafusp: participants assessedTebentafusp: meanTebentafusp: SDInvestigator's choice: participants assessedInvestigator's choice: meanInvestigator's choice: SD
Baseline (cycle 1)“173”“76.108”“20.233”“65”“74.872”“20.439”
Change from baseline at cycle 3“105”“0.952”“16.274”“35”“-0.238”“14.919”
Change from baseline at cycle 5“94”“-1.152”“20.797”“22”“-10.227”“22.557”
Change from baseline at cycle 9“57”“-2.193”“19.577”“13”“-8.333”“13.176”
Change from baseline at end of treatment“76”“-10.417”“20.911”“34”“-10.539”“23.148”
EQ-5D visual analogue scale (score 0 to 100)Tebentafusp: participants assessedTebentafusp: meanTebentafusp: SDInvestigator's choice: participants assessedInvestigator's choice: meanInvestigator's choice: SD
Baseline (cycle 1)“194”“81.0”“16.36”“78”“80.4”“18.31”
Change from baseline at cycle 3“136”“0.4”“14.69”“45”“-0.8”“14.28”
Change from baseline at cycle 5“108”“0.6”“15.61”“28”“-0.7”“14.38”
Change from baseline at cycle 9“71”“-0.9”“19.81”“14”“-3.3”“13.30”
Change from baseline at end of treatment“95”“-10.1”“22.53”“45”“-11.7”“21.40”